Skip to main content

Table 2 Summary of findings table

From: Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis

# First author Year Pilot ITT sample PP sample PP sample > median(43.5) Attrition rate(%) ‘Main’outcome identified Nature of‘main’outcome End-point
A01 Andrade 1991 N 44 33 N 25.0 Ritchie articular index Continuous 6 months
A05 Bell 2004 Y 62 53 Y 14.5 Tender point pain on palpation Continuous 3 months
A06 Bonne 2003 N 44 39 N 11.4 Hamilton Rating Scale for Anxiety (HAM-A) Continuous 10 weeks
A07 Brien 2011 N 32 23 N 28.1 Proportion of patients meeting ACR 20% improvement criteria (‘ACR20 response’) Dichotomous 28 weeks
A09 Cavalcanti 2003 N 28 20 N 28.6 Responders: patients with more than 50% reduction in pruritus score Dichotomous 60 days
A10 Chapman 1999 Y 61 50 Y 18.0 SRH-SLPD functional assessment tool: SRS (symptoms) sub-scale Continuous 4 months
A11 de Lange de Klerk 1994 N 175 170 Y 2.9 Daily total symptom score Continuous 1 year
A13 Fisher 2006 Y 38 27 N 28.9 VAS of overall symptom severity Continuous 13 weeks
A14 Frass 2005 N 70 67 Y 4.3 Patient survival Dichotomous 180 days
A16 Gaucher 1994 N 80 51 Y 36.3 Degree of dehydration Continuous 12 h
A18 Jacobs 1993 N 34 33 N 2.9 Number of days until fewer than 3 unformed stools for 2 consecutive days Continuous Up to 6 days
A19 Jacobs 1994 N 92 81 Y 12.0 Number of days until fewer than 3 unformed stools for 2 consecutive days Continuous Up to 5 days
A20 Jacobs 2001 Y 75 75 Y 0.0 Treatment failure Dichotomous 5 days (cumulative total)
A21 Jacobs 2000 N 126 116 Y 7.9 Number of days until fewer than 3 unformed stools for 2 consecutive days Continuous 5 days
A22 Jacobs 2005b Y 53 33 N 37.7 Hot flash severity score Continuous 12 months
A23 Jacobs 2005a Y 43 37 N 14.0 Conners Global Index–Parent (CGI-P)—total Continuous 17 weeks
A24 Jansen 1992 Y 10 4 N 60.0 Endoscopic appearance (grade) Continuous 12 months
A25 Kainz 1996 N 67 60 Y 10.4 Responders: patients with at least 50% reduction in area of skin affected by warts Dichotomous 8 weeks
A26 Katz 2005 Y 7 3 N 57.1 Hamilton Depression Scale (HAMD) Continuous 12 weeks
A30 Naudé 2010 N 33 30 N 9.1 Sleep Impairment Index (SII) summary score Continuous 4 weeks
A31 Rastogi ( a) 1999 N 50 42 N 16.0 CD4+ T-lymphocyte counts Continuous 6 months
A31 Rastogi ( b) 1999 N 50 38 N 24.0 CD4+ T-lymphocyte counts Continuous 6 months
A32 Sajedi 2008 N 24 16 N 33.3 Modified Ashworth Scale: measurement of muscle tone in right leg Continuous 4 months
A33 Siebenwirth 2009 N 24 14 N 41.7 MP (multiparameter dermatitis) score Continuous 32 weeks
A34 Steinsbekk 2005 N 251 199 Y 20.7 Parent-reported URTI total symptom score Continuous Duration of 12 weeks
A35 Straumsheim 2000 N 73 68 Y 6.8 Frequency of migraine attacks per month Continuous Last month of 4-month period
A36 Thompson 2005 Y 53 45 Y 15.1 MYMOP profile score Continuous 16 weeks
A37 Walach 1997 N 98 92 Y 6.1 Frequency of headaches per month Continuous Last month of 3-month period
A38 Weatherley- Jones 2004 N 103 86 Y 16.5 Responders: those with clinical improvement (Multidimensional Fatigue Inventory: mental fatigue) Dichotomous 7 months
A39 White 2003 N 89 74 Y 16.9 Childhood Asthma Questionnaire (CAQ) sub-scale for severity of symptoms Continuous 52 weeks
A40 Whitmarsh 1997 N 63 60 Y 4.8 Frequency of migraine attacks per month Continuous Last month of 4-month period
A41 Yakir 2001 Y 23 19 N 17.4 Menstrual distress questionnaire (MDQ) score Continuous Duration of 3 months (last 7 days per cycle)
  1. ITT intention to treat, PP per protocol, Y yes, N no.